<SEC-DOCUMENT>0000200406-24-000036.txt : 20240416
<SEC-HEADER>0000200406-24-000036.hdr.sgml : 20240416
<ACCEPTANCE-DATETIME>20240416121627
ACCESSION NUMBER:		0000200406-24-000036
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20240416
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240416
DATE AS OF CHANGE:		20240416

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		24846713

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>jnj-20240416.htm
<DESCRIPTION>8-K/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:5e69a9fe-8090-4c21-bac4-90702842b3b8,g:d9152f79-9a07-4b61-a53f-e9a26b042457,d:48b6395b807943f9917f9951764ec9fa-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:jnj="http://www.jnj.com/20240416" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>jnj-20240416</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-33">0000200406</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-34">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="jnj-20240416.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-16</xbrli:startDate><xbrli:endDate>2024-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-16</xbrli:startDate><xbrli:endDate>2024-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-16</xbrli:startDate><xbrli:endDate>2024-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-16</xbrli:startDate><xbrli:endDate>2024-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-16</xbrli:startDate><xbrli:endDate>2024-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-16</xbrli:startDate><xbrli:endDate>2024-04-16</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i48b6395b807943f9917f9951764ec9fa_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i48b6395b807943f9917f9951764ec9fa_4"></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K/A</ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 13 or 15(d) of The</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities Exchange Act of 1934</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported):&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">April&#160;16, 2024</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Johnson &amp; Johnson</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(Exact name of registrant as specified in its charter)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"><tr><td style="width:1.0%"/><td style="width:29.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">New Jersey</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">1-3215</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">22-1024240</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">One Johnson &amp; Johnson Plaza</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">New Brunswick</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">New Jersey</ix:nonNumeric>&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">08933</ix:nonNumeric>&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(Zip Code)&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">732</ix:nonNumeric>-<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">524-0400</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)&#160;</span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)&#160;</span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CFR 240.14d-2(b))&#160;</span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CFR 240.13e-4(c))</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934&#160;(&#167;240.12b-2&#160;of this chapter).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"/><td style="width:36.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.157%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-18">Common Stock, Par Value $1.00</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-19">JNJ</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-21">0.650% Notes Due May 2024</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-22">JNJ24C</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-23">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="dei:Security12bTitle" id="f-24">5.50% Notes Due November 2024</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="dei:TradingSymbol" id="f-25">JNJ24BP</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-26">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="dei:Security12bTitle" id="f-27">1.150% Notes Due November 2028</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="dei:TradingSymbol" id="f-28">JNJ28</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-29">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="dei:Security12bTitle" id="f-30">1.650% Notes Due May 2035</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="dei:TradingSymbol" id="f-31">JNJ35</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-32">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">EXPLANATORY NOTE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Amendment No. 1 to Form 8-K (&#8220;Amendment No. 1&#8221;) amends and supplements the Form 8-K filed by Johnson &amp; Johnson on April 16, 2024 (the &#8220;Initial Form 8-K&#8221;) solely to correct a typographical error of the full-year April 2024 guidance midpoint for operational sales from $88.0 to $88.9 in the press release attached as Exhibit 99.1 to the Initial Form 8-K. A copy of the correct press release is furnished herewith as Exhibit 99.1 to this Amendment No. 1.  Other than as set forth in this Amendment No. 1, no changes have been made to the Initial Form 8-K.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) &#160;&#160;&#160;&#160;Exhibits.&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.380%"><tr><td style="width:1.0%"/><td style="width:9.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit No.<br/>&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of Exhibit<br/>&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2024q1exhibit9911.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2024q1exhibit9911.htm">Press Release dated April 16, 2024 for the period ended March 31, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2024q1exhibit9911.htm">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Current Report on Form 8-K/A, formatted in Inline XBRL.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160; </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160; </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160; </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.456%"><tr><td style="width:1.0%"/><td style="width:6.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.135%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Johnson &amp; Johnson</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;(Registrant)<br/>&#160;<br/>&#160;<br/>&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 16, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Robert J. Decker, Jr.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert J. Decker, Jr.<br/>Controller<br/>(Principal Accounting Officer)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a2024q1exhibit9911.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i75c36ad202fc431bb98e3538f2c1ce04_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 99.1</font></div><div><img alt="logo.jpg" src="logo.jpg" style="height:18px;margin-bottom:5pt;vertical-align:text-bottom;width:192px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                      </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.333%"><tr><td style="width:1.0%"></td><td style="width:45.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Media contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tesia Williams </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">media-relations&#64;its.jnj.com</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investor contact&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jessica Moore</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">investor-relations&#64;its.jnj.com</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#eb1700;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:112%">Johnson &#38; Johnson Reports Q1 2024 Results</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:14.15pt">2024 First-Quarter reported sales growth of 2.3% to $21.4 Billion with operational growth of 3.9%* and adjusted operational growth of 4.0%*</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;padding-left:14.11pt">Adjusted operational growth excluding COVID-19 Vaccine of 7.7%*</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">2024 First-Quarter Earnings per share (EPS) increased to $2.20 and adjusted EPS increased to $2.71 or 12.4%* </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">Company increasing the midpoint for Full-Year 2024 operational sales</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">5</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%"> and adjusted operational EPS guidance </font></div><div style="margin-bottom:5pt"><font><br></font></div><div style="margin-bottom:5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">New Brunswick, N.J. (April 16, 2024)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8211; Johnson &#38; Johnson (NYSE&#58; JNJ) today announced results for first-quarter 2024. &#8220;Johnson &#38; Johnson&#8217;s solid first quarter performance reflects our sharpened focus and the progress in our portfolio and pipeline,&#8221; said Joaquin Duato, Chairman and Chief Executive Officer. &#8220;Our impact across the full spectrum of healthcare is unique in our industry, and the milestones achieved this quarter reinforce our position as an innovation powerhouse.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Unless otherwise noted, the financial results and earnings guidance included below reflect the continuing operations of Johnson &#38; Johnson. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Overall Financial Results</font></div><div><img alt="a1q24overallresultsv2.jpg" src="a1q24overallresultsv2.jpg" style="height:315px;margin-bottom:5pt;vertical-align:text-bottom;width:480px"></div><div style="margin-bottom:1.25pt;margin-top:0.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:112%;position:relative;top:-2.44pt;vertical-align:baseline"> 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:112%"> Non-GAAP financial measure&#59; refer to reconciliations of non-GAAP financial measures included in accompanying schedules</font></div><div style="margin-bottom:1.25pt;margin-top:0.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> 2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Excludes the impact of translational currency</font></div><div style="margin-bottom:1.25pt;margin-top:0.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> 3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Excludes the net impact of acquisitions and divestitures and translational currency</font></div><div style="margin-bottom:1.25pt;margin-top:0.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> 4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Excludes intangible amortization expense and special items</font></div><div style="margin-bottom:1.25pt;margin-top:0.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> 5 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Excludes COVID-19 Vaccine</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:112%;position:relative;top:-2.44pt;vertical-align:baseline"> 6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:112%"> Basic shares are used to calculate loss per share in the first quarter of 2023 as use of diluted shares when in a loss position would be anti-dilutive</font></div><div style="margin-bottom:1.25pt;margin-top:0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:125%">   Note&#58; values may have been rounded</font></div><div style="height:56.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">  Regional Sales Results</font></div><div><img alt="a1q24regionalsalesresultsv2.jpg" src="a1q24regionalsalesresultsv2.jpg" style="height:126px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"></div><div style="margin-top:0.5pt;text-indent:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline"> 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> Non-GAAP financial measure&#59; refer to reconciliations of non-GAAP financial measures included in accompanying schedules</font></div><div style="margin-bottom:1.25pt;margin-top:0.5pt;text-indent:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> 2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Excludes the impact of translational currency</font></div><div style="margin-bottom:1.25pt;margin-top:0.5pt;text-indent:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> 3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Excludes the net impact of acquisitions and divestitures and translational currency</font></div><div style="margin-bottom:1.25pt;margin-top:0.5pt;text-indent:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">   Note&#58; values may have been rounded</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">  Segment Sales Results</font></div><div><img alt="a1q24segmentsalesperforman.jpg" src="a1q24segmentsalesperforman.jpg" style="height:119px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"></div><div style="margin-bottom:1.25pt;margin-top:0.5pt;text-indent:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Non-GAAP financial measure&#59; refer to reconciliations of non-GAAP financial measures included in accompanying schedules</font></div><div style="margin-bottom:1.25pt;margin-top:0.5pt;text-indent:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> 2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Excludes the impact of translational currency</font></div><div style="margin-bottom:1.25pt;margin-top:0.5pt;text-indent:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> 3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Excludes the net impact of acquisitions and divestitures and translational currency          </font></div><div style="text-indent:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:112%">   Note&#58; values may have been rounded</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">First Quarter 2024 Segment Commentary&#58;</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operational sales* reflected below excludes the impact of translational currency. Adjusted operational sales* reflected below excludes the net impact of acquisitions and divestitures and translational currency.</font></div><div><font><br></font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Innovative Medicine</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Innovative Medicine worldwide operational sales, excluding the COVID-19 Vaccine, grew 8.3%*. Growth was driven by DARZALEX (daratumumab), ERLEADA (apalutamide), CARVYKTI (ciltacabtagene autoleucel), TECVAYLI (teclistamab-cqyv) and Other Oncology in Oncology, UPTRAVI (selexipag) and OPSUMIT (macitentan) in Pulmonary Hypertension, TREMFYA (guselkumab) in Immunology, and SPRAVATO (esketamine) in Neuroscience. Including the COVID-19 Vaccine,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Innovative Medicine worldwide operational sales grew 2.5%*.</font></div><div><font><br></font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">MedTech</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MedTech worldwide operational sales grew 6.3%* driven primarily by electrophysiology products and Abiomed in Cardiovascular, previously referred to as Interventional Solutions, and wound closure products in General Surgery. </font></div><div style="margin-bottom:5pt"><font><br></font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Notable New Announcements in the Quarter&#58;</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information contained in this section should be read together with Johnson &#38; Johnson&#8217;s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">www.sec.gov</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">www.jnj.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> or on request from Johnson &#38; Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company&#8217;s website at </font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">News Releases</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, as well as </font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Innovative Medicine News Center</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MedTech News &#38; Events</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">www.factsabouttalc.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">www.LLTManagementInformation.com. </font></div><div style="height:56.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.626%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="12" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Regulatory</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">CARVYKTI is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received At Least One Prior Line of Therapy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Johnson &#38; Johnson&#8217;s nipocalimab granted U.S. FDA Fast Track designation to reduce the risk of fetal neonatal alloimmune thrombocytopenia (FNAIT) in alloimmunized pregnant adults</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">U.S. FDA Approves OPSYNVI (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">U.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Johnson &#38; Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of TREMFYA (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr><tr style="height:33pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Johnson &#38; Johnson submits application to the European Medicines Agency for DARZALEX (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr><tr style="height:33pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">RYBREVANT (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Janssen Receives Positive CHMP Opinion for CARVYKTI (ciltacabtagene autoleucel&#59; cilta-cel) for Treatment in Earlier Lines of Relapsed and Refractory Multiple Myeloma</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">TECVAYLI (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Johnson &#38; Johnson&#8217;s nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr><tr style="height:33pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Johnson &#38; Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) based regimen for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr><tr style="height:24pt"><td colspan="3" rowspan="7" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Data Release</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Unique molecular properties of nipocalimab enabling differentiated potential in treating generalized myasthenia gravis to be presented at American Academy of Neurology&#8217;s 2024 Annual Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Johnson &#38; Johnson to Showcase its Broad Scientific Leadership and Latest Innovations to Combat Cardiovascular Disease at ACC.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">RYBREVANT (amivantamab-vmjw) data at ELCC advance Johnson &#38; Johnson&#8217;s ambition to transform the standard of care for patients with EGFR-mutated non-small cell lung cancer</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Investigational targeted oral peptide JNJ-2113 demonstrated positive results in moderate-to-severe plaque psoriasis in Phase 2b study published in New England Journal of Medicine</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Johnson &#38; Johnson reports positive topline results for Nipocalimab from a Phase 3 pivotal study in generalized myasthenia gravis (gMG) and a Phase 2 study in Sj&#246;gren&#8217;s Disease (SjD)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Johnson &#38; Johnson Highlights Ambition to Transform the Treatment of Prostate Cancer and Bladder Cancer through Data Presentations at ASCO GU</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Product Launch</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Biosense Webster Announces CE Mark approval in Europe for VARIPULSE Pulsed Field Ablation (PFA) Platform</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Other</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Johnson &#38; Johnson to Acquire Shockwave Medical</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Johnson &#38; Johnson Completes Acquisition of Ambrx</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Press Release</font></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:117%;position:relative;top:-2.62pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:117%">Subsequent to the quarter </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:56.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Full-Year 2024 Guidance&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Johnson &#38; Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These items are uncertain, depend on various factors, and could be material to Johnson &#38; Johnson's results computed in accordance with GAAP. </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.200%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e8e6e3;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:117%">($ in Billions, except EPS)</font></div></td><td colspan="3" style="background-color:#e8e6e3;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:117%">April 2024</font></div></td><td colspan="3" style="background-color:#e8e6e3;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:117%">January 2024</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Adjusted Operational Sales</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:117%;position:relative;top:-3.48pt;vertical-align:baseline">1,2,5</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Change vs. Prior Year &#47; Mid-point</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">5.5% &#8211; 6.0% &#47; 5.8%</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">5.0% &#8211; 6.0% &#47; 5.5%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Operational Sales</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:117%;position:relative;top:-3.48pt;vertical-align:baseline">2,5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#47; Mid-point</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Change vs. Prior Year &#47; Mid-point</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">$88.7B &#8211; $89.1B &#47; $88.9B<br>5.5% &#8211; 6.0% &#47; 5.8%</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">$88.2B &#8211; $89.0B &#47; $88.6B<br>5.0% &#8211; 6.0% &#47; 5.5%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Estimated Reported Sales</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:117%;position:relative;top:-3.48pt;vertical-align:baseline">3,5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#47; Mid-point</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Change vs. Prior Year &#47; Mid-point</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">$88.0B &#8211; $88.4B &#47; $88.2B<br>4.7% &#8211; 5.2% &#47; 5.0%</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">$87.8B &#8211; $88.6B &#47; $88.2B<br>4.5% &#8211; 5.5% &#47; 5.0%</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Adjusted Operational EPS (Diluted)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:117%;position:relative;top:-3.48pt;vertical-align:baseline">2,4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#47; Mid-point</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Change vs. Prior Year &#47; Mid-point</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">$10.60 &#8211; $10.75 &#47; $10.68<br>6.9% &#8211; 8.4% &#47; 7.7%</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">$10.55 &#8211; $10.75 &#47; $10.65</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">6.4% &#8211; 8.4% &#47; 7.4%</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Adjusted EPS (Diluted)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:117%;position:relative;top:-3.48pt;vertical-align:baseline">3,4 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#47; Mid-point</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Change vs. Prior Year &#47; Mid-point</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">$10.57 &#8211; $10.72 &#47; $10.65</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">6.6% &#8211; 8.1% &#47; 7.4%</font></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">$10.55 &#8211; $10.75 &#47; $10.65</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">6.4% &#8211; 8.4% &#47; 7.4%</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:112%;position:relative;top:-2.44pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Non-GAAP financial measure&#59; excludes the net impact of acquisitions and divestitures</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:112%;position:relative;top:-2.44pt;vertical-align:baseline">2 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Non-GAAP financial measure&#59; excludes the impact of translational currency</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:112%;position:relative;top:-2.44pt;vertical-align:baseline">3 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Calculated using Euro Average Rate&#58; April 2024 &#61; $1.08 and January 2024 &#61; $1.09 (Illustrative purposes only)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:112%;position:relative;top:-2.44pt;vertical-align:baseline">4 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Non-GAAP financial measure&#59; excludes intangible amortization expense and special items </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:112%;position:relative;top:-2.44pt;vertical-align:baseline">5 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Excludes COVID-19 Vaccine </font></div><div style="margin-bottom:1.25pt;margin-top:0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:112%">  Note&#58; percentages may have been rounded</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Other modeling considerations will be provided on the</font><font style="color:#00b0f0;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%;text-decoration:underline">webcast</font><font style="color:#00b0f0;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%;text-decoration:underline">.</font></div><div><font><br></font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Webcast Information&#58;</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Johnson &#38; Johnson will conduct a conference call with investors to discuss this earnings release today at 8&#58;30 a.m., Eastern Time.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the </font><font style="background-color:#ffffff;color:#0563c1;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Johnson &#38; Johnson website</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at </font><font style="background-color:#ffffff;color:#0563c1;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">events-and-presentations</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">About Johnson &#38; Johnson&#58;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">At Johnson &#38; Johnson,&#8239;we believe health is everything. Our strength in healthcare innovation empowers us to build a&#8239;world where complex diseases are prevented, treated, and cured,&#8239;where treatments are smarter and less invasive, and&#8239;solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at </font><font style="background-color:#ffffff;color:#0070c0;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">https&#58;&#47;&#47;www.jnj.com&#47;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Non-GAAP Financial Measures&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">* &#8220;Operational sales growth&#8221; excluding the impact of translational currency, &#8220;adjusted operational sales growth&#8221; excluding the net impact of acquisitions and divestitures and translational currency, as well as &#8220;adjusted net earnings&#8221;, &#8220;adjusted diluted earnings per share&#8221; and &#8220;adjusted operational diluted earnings per share&#8221; excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and </font></div><div style="height:56.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at </font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">quarterly results</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Copies of the financial schedules accompanying this earnings release are available on the company&#8217;s website at </font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">quarterly results</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products&#47;franchises. Additional information on Johnson &#38; Johnson, including adjusted income before tax by segment, an </font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Innovative Medicine pipeline</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%"> of selected compounds in late stage development and a copy of today&#8217;s earnings call presentation can also be found in the Investor Relations section of the company's website at </font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">quarterly results</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Note to Investors Concerning Forward-Looking Statements&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">This press release contains &#8220;forward-looking statements&#8221; as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things&#58; future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson &#38; Johnson. Risks and uncertainties include, but are not limited to&#58; economic factors, such as interest rate and currency exchange rate fluctuations&#59; competition, including technological advances, new products and patents attained by competitors&#59; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals&#59; uncertainty of commercial success for new and existing products&#59; challenges to patents&#59; the impact of patent expirations&#59; the ability of the Company to successfully execute strategic plans, including restructuring plans&#59; the impact of business combinations and divestitures&#59; manufacturing difficulties or delays, internally or within the supply chain&#59; product efficacy or safety concerns resulting in product recalls or regulatory action&#59; significant adverse litigation or government action, including related to product liability claims&#59; changes to applicable laws and regulations, including tax laws and global health care reforms&#59; trends toward health care cost containment&#59; changes in behavior and spending patterns of purchasers of health care products and services&#59; financial instability of international economies and legal systems and sovereign risk&#59; increased scrutiny of the health care industry by government agencies&#59; the Company&#8217;s ability to realize the anticipated benefits from the separation of Kenvue Inc&#59; and Kenvue&#8217;s ability to succeed as a standalone publicly traded company. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson &#38; Johnson&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; and &#8220;Item 1A. Risk Factors,&#8221; and in Johnson &#38; Johnson&#8217;s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at </font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">www.sec.gov, www.jnj.com</font><font style="color:#0563c2;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">or on request from Johnson &#38; Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson &#38; Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.</font></div><div><font><br></font></div><div style="height:56.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>jnj-20240416.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:5e69a9fe-8090-4c21-bac4-90702842b3b8,g:d9152f79-9a07-4b61-a53f-e9a26b042457-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:jnj="http://www.jnj.com/20240416" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.jnj.com/20240416">
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20240416_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20240416_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20240416_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.jnj.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="jnj_A0.650NotesDue2024Member" abstract="true" name="A0.650NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A1.650NotesDue2035Member" abstract="true" name="A1.650NotesDue2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A5.50NotesDue2024Member" abstract="true" name="A5.50NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="jnj_A1.150NotesDue2028Member" abstract="true" name="A1.150NotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>jnj-20240416_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:5e69a9fe-8090-4c21-bac4-90702842b3b8,g:d9152f79-9a07-4b61-a53f-e9a26b042457-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.jnj.com/role/Cover" xlink:type="simple" xlink:href="jnj-20240416.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_3e360f91-972b-4b0c-97f9-7c8282f53f2f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_EntitiesTable_3e360f91-972b-4b0c-97f9-7c8282f53f2f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_eb3437bd-1a57-498b-9bef-78c8a0c8ee5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_3e360f91-972b-4b0c-97f9-7c8282f53f2f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_eb3437bd-1a57-498b-9bef-78c8a0c8ee5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_eb3437bd-1a57-498b-9bef-78c8a0c8ee5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_eb3437bd-1a57-498b-9bef-78c8a0c8ee5c" xlink:to="loc_us-gaap_ClassOfStockDomain_eb3437bd-1a57-498b-9bef-78c8a0c8ee5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_eda20e47-6941-4864-a56a-f2f99d5253c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_eb3437bd-1a57-498b-9bef-78c8a0c8ee5c" xlink:to="loc_us-gaap_ClassOfStockDomain_eda20e47-6941-4864-a56a-f2f99d5253c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_02108216-1ab7-433f-9653-540e0b37c52f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_eda20e47-6941-4864-a56a-f2f99d5253c8" xlink:to="loc_us-gaap_CommonStockMember_02108216-1ab7-433f-9653-540e0b37c52f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_2313a3ad-7885-484a-a9f3-3ef8212860c0" xlink:href="jnj-20240416.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_eda20e47-6941-4864-a56a-f2f99d5253c8" xlink:to="loc_jnj_A0.650NotesDue2024Member_2313a3ad-7885-484a-a9f3-3ef8212860c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_2b32ea08-0ecd-4fd6-af0c-3eeaebcbf752" xlink:href="jnj-20240416.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_eda20e47-6941-4864-a56a-f2f99d5253c8" xlink:to="loc_jnj_A5.50NotesDue2024Member_2b32ea08-0ecd-4fd6-af0c-3eeaebcbf752" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_2d6998ae-b550-4db6-8538-a5d43ac52bc8" xlink:href="jnj-20240416.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_eda20e47-6941-4864-a56a-f2f99d5253c8" xlink:to="loc_jnj_A1.150NotesDue2028Member_2d6998ae-b550-4db6-8538-a5d43ac52bc8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_c8a45087-a8e2-4d5a-a455-e6a491fa6e2a" xlink:href="jnj-20240416.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_eda20e47-6941-4864-a56a-f2f99d5253c8" xlink:to="loc_jnj_A1.650NotesDue2035Member_c8a45087-a8e2-4d5a-a455-e6a491fa6e2a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5719238a-d778-4022-800b-ca273c589a30" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_DocumentType_5719238a-d778-4022-800b-ca273c589a30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_70fb13e6-e266-4008-b08d-a3576c0fafde" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_DocumentPeriodEndDate_70fb13e6-e266-4008-b08d-a3576c0fafde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0abaccb8-17be-4817-a9b1-ce3d9768204c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_EntityRegistrantName_0abaccb8-17be-4817-a9b1-ce3d9768204c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f09becb2-5048-438b-9d6f-120267e119a0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f09becb2-5048-438b-9d6f-120267e119a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_0959e166-7c3c-43e6-a93b-998763e08580" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_EntityFileNumber_0959e166-7c3c-43e6-a93b-998763e08580" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_55225372-ec20-4e20-8327-6a64c8532744" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_EntityTaxIdentificationNumber_55225372-ec20-4e20-8327-6a64c8532744" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_aeb00ca1-0471-48c0-b71b-e2a1c311dcd9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_EntityAddressAddressLine1_aeb00ca1-0471-48c0-b71b-e2a1c311dcd9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c8bdffb6-68bd-406e-84cb-c88375976bb1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_EntityAddressCityOrTown_c8bdffb6-68bd-406e-84cb-c88375976bb1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0d62a11d-3257-455a-b5d2-e85daf4f3184" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_EntityAddressStateOrProvince_0d62a11d-3257-455a-b5d2-e85daf4f3184" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e4b6b5f7-0a65-4e9a-8751-5fa37cf6b748" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_EntityAddressPostalZipCode_e4b6b5f7-0a65-4e9a-8751-5fa37cf6b748" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c9ad89a4-14a0-4943-a4ac-a3aa7542f9a4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_CityAreaCode_c9ad89a4-14a0-4943-a4ac-a3aa7542f9a4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_86e2104a-ba05-4eea-8588-19ad3247c51e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_LocalPhoneNumber_86e2104a-ba05-4eea-8588-19ad3247c51e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_5dbd1e3c-de14-431f-986f-2f33c54be357" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_WrittenCommunications_5dbd1e3c-de14-431f-986f-2f33c54be357" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_550a6955-4352-4b31-8f95-a0bc37a8e0b0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_SolicitingMaterial_550a6955-4352-4b31-8f95-a0bc37a8e0b0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_b7e47891-c267-4675-ae8d-b23861e6b913" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_PreCommencementTenderOffer_b7e47891-c267-4675-ae8d-b23861e6b913" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_7192517d-ec53-4c56-bde4-4c430fa22f0a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_7192517d-ec53-4c56-bde4-4c430fa22f0a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d1215fdf-6f5b-492e-99eb-044f603238f3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_EntityEmergingGrowthCompany_d1215fdf-6f5b-492e-99eb-044f603238f3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1a006e71-7597-48d5-b45d-4a53de593e44" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_Security12bTitle_1a006e71-7597-48d5-b45d-4a53de593e44" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9f2a1918-8d21-47d8-8f6e-8d14c2530f18" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_TradingSymbol_9f2a1918-8d21-47d8-8f6e-8d14c2530f18" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_32704b8b-d825-4a63-a1c8-fa3b8bfd36b2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_SecurityExchangeName_32704b8b-d825-4a63-a1c8-fa3b8bfd36b2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_30b6162d-9ed7-4eaf-9fa1-f0e58a7bf3f8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_EntityCentralIndexKey_30b6162d-9ed7-4eaf-9fa1-f0e58a7bf3f8" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5269ac15-b2a3-4a0d-abd2-86624ff96aa4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_AmendmentFlag_5269ac15-b2a3-4a0d-abd2-86624ff96aa4" xlink:type="arc" order="21"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>jnj-20240416_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:5e69a9fe-8090-4c21-bac4-90702842b3b8,g:d9152f79-9a07-4b61-a53f-e9a26b042457-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityInformationLineItems_6ec7e7dc-3a66-403a-b452-f4d02b156cb3_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_49e2014e-5280-4d56-8a1f-b2e959948b12_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_520919e3-c152-415b-80c7-71a9cee6e305_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Par Value $1.00</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_bb764fba-27f2-41c2-b90f-5136a21ef7fd_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_b60ba6da-76bd-4ec5-9504-a83fd3f79bea_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_31ef71b3-b290-478c-a0b9-29f2d84400af_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_31a56379-8c0b-45a8-9414-1b80da47e4a5_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ead43ca0-53e5-413e-868f-67729cc9242c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_8133a88d-bcb1-4765-9858-0e9c363f9515_terseLabel_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.650% Notes Due May 2035</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_label_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_documentation_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member" xlink:href="jnj-20240416.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.650NotesDue2035Member" xlink:to="lab_jnj_A1.650NotesDue2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7b993cd4-8dbf-42ee-8ede-d413ce91eaa8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0ef3aea0-0848-4bfb-a095-e8160c395acc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_365684dc-1ca1-4c28-8e2e-cc41073e9ec0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_083bf515-c51a-48d7-99a1-6a1025e99c5f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_2fe462f7-b221-4ef2-a284-aec930ab8471_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a6613995-299e-45b4-8653-772aff38f803_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a1636593-ad77-42b2-8c28-51f1b11413e7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8325c659-05c1-44ec-8d76-3b95bc8b6813_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_ec193c13-7990-4c63-b4d0-032363a6b0cf_terseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.150% Notes Due November 2028</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_label_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_documentation_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member" xlink:href="jnj-20240416.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.150NotesDue2028Member" xlink:to="lab_jnj_A1.150NotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_1811f610-c8c4-4aed-98ef-1c7945743e00_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_04f5c78f-691c-42dc-8a0d-723b59eca486_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_e501988f-958b-4e8e-9bce-1b5cd82b2bea_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8c8a4d4b-3a42-4279-b69b-8a5c7dc3f793_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0aab7219-8d73-41f0-b246-4bfbb7a7db1f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_fbdb9034-5d0c-4a3b-8c8d-ec34c3282bbb_terseLabel_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.50% Notes Due November 2024</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member" xlink:href="jnj-20240416.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.50NotesDue2024Member" xlink:to="lab_jnj_A5.50NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_aa36848d-5905-4a72-b8c1-9b84872b9ce9_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_5b7df5b0-b766-416c-8695-f06ffbfdbc4f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d5c78605-b1d7-4bbd-9d91-ed69cc07b17b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_6702851a-7258-43bc-be6b-42fccea4c950_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5a0de1fe-62d9-4265-abb9-aa2ac58be419_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_d3e7085c-7ba6-4b40-bcaa-cb176569ee83_terseLabel_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.650% Notes Due May 2024</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member" xlink:href="jnj-20240416.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0.650NotesDue2024Member" xlink:to="lab_jnj_A0.650NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6963dfa1-ed47-4665-984b-3882f5cc2b01_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_fc0d0268-b0d5-4ca1-a754-0b5a28e39286_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>jnj-20240416_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:5e69a9fe-8090-4c21-bac4-90702842b3b8,g:d9152f79-9a07-4b61-a53f-e9a26b042457-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com/role/Cover" xlink:type="simple" xlink:href="jnj-20240416.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2a034bd4-233f-414f-849c-b79b971f9aca" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_3e360f91-972b-4b0c-97f9-7c8282f53f2f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a034bd4-233f-414f-849c-b79b971f9aca" xlink:to="loc_dei_EntitiesTable_3e360f91-972b-4b0c-97f9-7c8282f53f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_eb3437bd-1a57-498b-9bef-78c8a0c8ee5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_3e360f91-972b-4b0c-97f9-7c8282f53f2f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_eb3437bd-1a57-498b-9bef-78c8a0c8ee5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_eda20e47-6941-4864-a56a-f2f99d5253c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_eb3437bd-1a57-498b-9bef-78c8a0c8ee5c" xlink:to="loc_us-gaap_ClassOfStockDomain_eda20e47-6941-4864-a56a-f2f99d5253c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_02108216-1ab7-433f-9653-540e0b37c52f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_eda20e47-6941-4864-a56a-f2f99d5253c8" xlink:to="loc_us-gaap_CommonStockMember_02108216-1ab7-433f-9653-540e0b37c52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_2313a3ad-7885-484a-a9f3-3ef8212860c0" xlink:href="jnj-20240416.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_eda20e47-6941-4864-a56a-f2f99d5253c8" xlink:to="loc_jnj_A0.650NotesDue2024Member_2313a3ad-7885-484a-a9f3-3ef8212860c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_2b32ea08-0ecd-4fd6-af0c-3eeaebcbf752" xlink:href="jnj-20240416.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_eda20e47-6941-4864-a56a-f2f99d5253c8" xlink:to="loc_jnj_A5.50NotesDue2024Member_2b32ea08-0ecd-4fd6-af0c-3eeaebcbf752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_2d6998ae-b550-4db6-8538-a5d43ac52bc8" xlink:href="jnj-20240416.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_eda20e47-6941-4864-a56a-f2f99d5253c8" xlink:to="loc_jnj_A1.150NotesDue2028Member_2d6998ae-b550-4db6-8538-a5d43ac52bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_c8a45087-a8e2-4d5a-a455-e6a491fa6e2a" xlink:href="jnj-20240416.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_eda20e47-6941-4864-a56a-f2f99d5253c8" xlink:to="loc_jnj_A1.650NotesDue2035Member_c8a45087-a8e2-4d5a-a455-e6a491fa6e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_3e360f91-972b-4b0c-97f9-7c8282f53f2f" xlink:to="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5719238a-d778-4022-800b-ca273c589a30" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_DocumentType_5719238a-d778-4022-800b-ca273c589a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_70fb13e6-e266-4008-b08d-a3576c0fafde" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_DocumentPeriodEndDate_70fb13e6-e266-4008-b08d-a3576c0fafde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0abaccb8-17be-4817-a9b1-ce3d9768204c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_EntityRegistrantName_0abaccb8-17be-4817-a9b1-ce3d9768204c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f09becb2-5048-438b-9d6f-120267e119a0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f09becb2-5048-438b-9d6f-120267e119a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_0959e166-7c3c-43e6-a93b-998763e08580" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_EntityFileNumber_0959e166-7c3c-43e6-a93b-998763e08580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_55225372-ec20-4e20-8327-6a64c8532744" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_EntityTaxIdentificationNumber_55225372-ec20-4e20-8327-6a64c8532744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_aeb00ca1-0471-48c0-b71b-e2a1c311dcd9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_EntityAddressAddressLine1_aeb00ca1-0471-48c0-b71b-e2a1c311dcd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c8bdffb6-68bd-406e-84cb-c88375976bb1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_EntityAddressCityOrTown_c8bdffb6-68bd-406e-84cb-c88375976bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0d62a11d-3257-455a-b5d2-e85daf4f3184" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_EntityAddressStateOrProvince_0d62a11d-3257-455a-b5d2-e85daf4f3184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e4b6b5f7-0a65-4e9a-8751-5fa37cf6b748" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_EntityAddressPostalZipCode_e4b6b5f7-0a65-4e9a-8751-5fa37cf6b748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c9ad89a4-14a0-4943-a4ac-a3aa7542f9a4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_CityAreaCode_c9ad89a4-14a0-4943-a4ac-a3aa7542f9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_86e2104a-ba05-4eea-8588-19ad3247c51e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_LocalPhoneNumber_86e2104a-ba05-4eea-8588-19ad3247c51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_5dbd1e3c-de14-431f-986f-2f33c54be357" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_WrittenCommunications_5dbd1e3c-de14-431f-986f-2f33c54be357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_550a6955-4352-4b31-8f95-a0bc37a8e0b0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_SolicitingMaterial_550a6955-4352-4b31-8f95-a0bc37a8e0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_b7e47891-c267-4675-ae8d-b23861e6b913" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_PreCommencementTenderOffer_b7e47891-c267-4675-ae8d-b23861e6b913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_7192517d-ec53-4c56-bde4-4c430fa22f0a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_7192517d-ec53-4c56-bde4-4c430fa22f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d1215fdf-6f5b-492e-99eb-044f603238f3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_EntityEmergingGrowthCompany_d1215fdf-6f5b-492e-99eb-044f603238f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1a006e71-7597-48d5-b45d-4a53de593e44" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_Security12bTitle_1a006e71-7597-48d5-b45d-4a53de593e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9f2a1918-8d21-47d8-8f6e-8d14c2530f18" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_TradingSymbol_9f2a1918-8d21-47d8-8f6e-8d14c2530f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_32704b8b-d825-4a63-a1c8-fa3b8bfd36b2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_SecurityExchangeName_32704b8b-d825-4a63-a1c8-fa3b8bfd36b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_30b6162d-9ed7-4eaf-9fa1-f0e58a7bf3f8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_EntityCentralIndexKey_30b6162d-9ed7-4eaf-9fa1-f0e58a7bf3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5269ac15-b2a3-4a0d-abd2-86624ff96aa4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_be0d8b33-37d2-4f94-b4ef-4833a67c4aff" xlink:to="loc_dei_AmendmentFlag_5269ac15-b2a3-4a0d-abd2-86624ff96aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>a1q24overallresultsv2.jpg
<TEXT>
begin 644 a1q24overallresultsv2.jpg
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MRG2O_EGW]G_F_]6_^I<G^4<2<;.:I_*8KZ=O*7V_:G,KIH^JB:L?-'*@.Y]
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M_4L^;BT =;T,:=FO-B-EJ8?49]9'TQBPD0+.RZ<T-@4:WXQ)Z9Z74A"IK,9
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M6^QI3RC]D\C#O7;M3[/+<V -)DY25X4F.- I/\DO#[]4!65TX?OEZI>3F-+
M+QM=;GF)DJZ\B3WC2U9U1#Y F%N.0>,$VEKU!:L'#6F(\8#:5+D<I_O9OQW*
MJSW_%I[&3XU!T*;:U7@N?=  ]>03QHKM<^%;/O7XX-O+;2&_9MO.WO8T5Y3K
M],[DX5Z[]J?9Y3FP#A,GJ:M"R>J2!5UTE-%![ZBN7UAY"3IJ;X5?.JJO2Y2Z
M6Q?2GO%-;.7G8\$O>>'C(D^7\\3DZVE>C,?+91D?U\HO/B_R*>=XVN0#\M5'
MKD4RU1>T0]XT=R!M>M"<ZW-"?4QU]K;'>!D/XOM3P#=^N->N_6EV>0XKWY^D
M[EV@K8-;%X0N/K_D@&_R=9GY1:NZ?M%A:URZO/R"H>[6)8JMRP]41GV<&]^$
MVL@+7W5S?-Y>SC'' [2K=E2><H*RI F5\7*TX6OD?@;*NE_(\_)\Y_P\+?-I
MBS;5A^;EOG T1Y\7Y+@IX[Z1/S7V]$7. U0^?0\:QXJM]D#S%I[W[N3A7KOV
MI]G/A#&L-)V[.NLF^9FE-)WE#NEY9C\#QC%QDKHJE%#.+[,D+P&^J:-Z_-2E
M@B/=<;J@I+RP<E'2Z>K+Q^?E42[(UOBV\'IHNL@8GRX]*=O6Y>\2TX,&:-?+
MJYSF+1M1-_T,RD>^7H#M/@1/RS'3OGSG^=/&$M.\<XP9#_1!7QIOQ@>D;WP>
M4Y_G6+6G^=*F4/LJP_>>6#HB>;C7KOUI]JO!V/R\.X?.,,%9IWN,;V^+[TO:
MOB<^9N<D=57HGN \.? =\0 IY9W(P[UV[4^S7PGN&>Z;O4S_6.8?BOH'&(\7
M;X^RK\)J+$]_T+S[A=\'37E7\G"O7?O3[%=!OQGVQ\DYN)OR ;1ZT+S2;V=@
MY?NG/6BT &CK/TL<G3YHRKN2AWOMVI]FOPK3XV2+U0/([RN^><1P/^L_\;\*
MC'WB:0^:4LJQR<.]=NU/LU^!Z3\=G6/K/T_1%E(^9?FMC?KQO&?!&";ZH"FE
M7$4>[K5K?YK]"O!;E$M_@\(\]OP?*_AO9_0;&R#MF?\)BO%/]$%32KF*<X=]
M[=KO;K\"/#0N^9\UZ#\W[?F?>M"V?O-#'7W3WR5]WIJ5[[_\H.&51CW7"ARP
M559MK7YUIE]Y42Y_S:9%FK1GX9)5/5ZF:G?KUVZ:ZZIOC??>_R>]ZN<:'VS!
MN%<O=/PB']VZW_(ZY.%>N_:GV:\ 8[GD'N'<WO,;'>X.O^/H1_?M6SYH<$I>
MZGJ4Y$5&6CJ112#=+T;LE:/4-M ^WW+PZN)6'RJW!\I/;>5\&<_J4:/Q^=P<
MYK@GJ%X1/=:FN>%OK5]NB/)>Y.%>N_:GV<]&]TS>55MP/J_N6(>SV^]-;)WY
MW%VKN^T1,.>)JQ\T.&1U69'N>5ME\R%"V=4X<*(60@LIAV<[#H[?\WC0XT?R
MMI27[=.N+[K#G%?]TM8S ^):F#^^0.?&CU_V;)QR3/)PKUW[T^QGHWMO!7F<
MU0[WTKFSF_SI[*8]M+K/'\5JSE<_:"9'.;KX^4G9U:4/.$?.TP)EVTI7.]FN
M\O/! 7O& 'J<3&TQGNEQLA4<U)GZ5;JW3SNDN1+/R[$P!L^7_W(NRIO*BLR?
MYD>9K4VA^9SS>3DNK*\?[K5K?YI=GL/*]U<]:*8+?X7*;L'%Z"\^OMT&'CR>
MEH^4<V/B 9 7]XJI+5WR">UN7>SDYTN7>7A:S@WHR\M@>S]>AW0?F_LFY\*W
ME]6\E)\V3',X]Z 1U/6VRON0AWOMVI]FE^> _R=.4E>%DG./!V?U$'"X&+GX
MQ'2I8I,NR".-L<"Y,=&^U]]BU19I?K'K(;%UL6\]-L0T9G_T,&[WCU"]U=S(
MS[E,X_7Q3&VI#8<RT[Q)\_2L5]Z'/-QKU_XTNSP'UF#B)'55*-&E/%W$"1??
MN7:Y *??4.ABG-K0&'01Y\6=W.)! Z1+&K=?X(G&J;XI.SU.@#QO7S[QW\8D
MZ8<DY\)W^L'3^%[)_4%YG[?/B;&JSEZ?E^.1AWOMVI]FE^? .DQ<]: !RJXN
M*[]$SUVXP 68_TG#+_XI/]O-B]O)LGR[LLY66\F>AY(_2"B?#R!_R C*J\ZC
M'S2KMK;(]2GO#['BAWOMVI]FE^>P\OW5#YJM2Y8\_Q?[5MG5XT$7-1?M5KXN
MWU4[X(^C/4QMJ3]/V^K343G-)5&>PWCELW/CG^J+'.-4UM.F!U<I$WFXUZ[]
M:79Y#OA_XNH'#5 ^'RH\7DCG(G6X*/-2U@6_ND!I>^H#],!0/ZO'A?K(\6RQ
M:HOQ^V\BTMZ"LK0YE2?/?2 ?^KRQO0S?I.6W4/F<"]];#YK)7QI/*4X>[K5K
M?YI=G@-K,'&2NBJTA2X[UPI=O'O*@B[CO(!A]:"9E ^3<^0CP/%V]SYF8.MA
ME6.GW=4CQ>6D;[$AY\+WUH,&-%8I'Z*E0![NM6M_FEV> ^LP<9*Z*E1**<FE
MAW_MVN]FE^>P\GT?-*64J\C#O7;M3[/+<\#_$WW0E%*N(@_WVK4_S2[/@368
MZ(.FE'(5>;C7KOUI=GD.K,-$'S2EE*NX]/"O7?O=[/(<5K[_YD%35555557U
MRIKXYD%32BFEE/*J]$%32BFEE,/3!TTII912#D\?-*644DHY/'W0E%)**>7P
M]$%32BFEE,/3!TTIY?#T#Z4^E_J_O )W>]#HKUY?4I>R^NO._&7I[[___M?O
M6\!?E[[TKVLG/KY$?XEZRM_Z*]U;K/H"#A#:7.F>7#N?KW+NT&1</5@_B]5?
MDW<X1Y2_)SZFO95[T?.FOZY_:9]'Y1[^SS:WT+F;?(K_5\@OTIZS^IS/E$>Y
MA'3.WV?#."9.4E>%MB HY:"MB]FYI.PEW.H"WAJ?!U#V<TW_6WT! 3<='N\(
M?I-OMR#_$P^O3T5[COC0NN>^(=T/8+ZG ]FAC:W#F3;]$4-YWXOYC[$]?1Z1
M>_A?;0H];B96Y\*G^']%WC>^3BOPF=80TF=\*^;Y]GCG^U7NHE6LG*2N"FV!
M<YAD!M<6]..;X58\\D&3&QCZH/D:FJ=ON 2?X^>M,N6]\$-6ZTZL:/]I3SJZ
M!%=[47MUQ91//^I?[5-.G.OSJ-S#_[23YQKEI[.0?BCO?7R2_U?XNHC)K\XY
MGU%?:^!K#.[_9[,:RTGJI0/6IL<9_ITH&!%.XJ><Y@^A:6-DFFQ)"ZK^);4/
MGLY8DJWQ)>I?_7FYR0<Y7@\V3\_ %.<"5"@P5VWRC91'F]C:%$KW ,[Y:"SI
M+P=;>913'\+[0I.?J3=!V^IO5::\'XI1F-8]8VP/Q-U6#"GV':\SY0/Y4TP?
MF7OX?V(Z#W3>D.[^_B3_7P+SSS/9P6?X3NC>\#->_J,=K:N?O:_ M/9PDKHJ
MM"(#&6<H\$6F49Y^Y#1O(X,6/"TO6/"V5OF^$'RK/3@WOL3'DVUE_RKKX\G^
MMOH"RN\)I&Q'?2MXZ=-M4)K7PU9_.1_&XK;RU6;Z0V/P34$;(ML77L91_Y+'
M7GE?%$>L_Q0;Q &QI7A6V2THF_&4^XS\W*NR&=/66-Z)>_@_T7HXG NTQ4^-
M07R2__?"O-U'$^EG_)6V8ER^Q/^7KN>]6<WS)/6<,Q+*$U@B':H+RU&0JA[.
MPW&000N>MKH 1>8S'K7ML#BTNV=\28Z1MM1']J]^G.QSJR^@#<I,TL:=_*%Y
MT!],!\8J30$]S4=YPN?HWP+?R#^,-_N;N%69\CXHGB5??^*+-(\]TK9B)//5
MOO:4H(SZ]+Q5+--N[I%WX-;^%]11FWEV4%\^5SGQ:?[?0N<TROB=P#\JC[^2
MS*,\_O<8F.H]$L8P<9*Z*C21 0::L )S%71>!F?).5.;F499;)1.S0O8%R[%
MV/:,+\GQJ$_2LW^^5_(RJ[[ -_4>*._]J&WWLSB7-CUH<BQ*T]I3Q\D^?&RK
M>?F:T!YM)%ZF? ZLNV)-,4!\33%"F:V]E?AYH-CW>*8?Y=/N%(.4N62_'HU[
M^I_VU X^]'.#=FA/?*K_S\'\W6\)/G3_\$V:SOB$=%]GU27MF7[V6'!.4E>%
M)I@<Y2?)H4QX"CK**-#]PLN@A2D-E(ZT"?(")GW::&+/^))I//1!6O:OM"VV
M^H*]@4,YVM)\=>BH;=(ST,^EY7RFL2A-_>5\ISZ =,K[&"=H=\_\RV>@_>JQ
M27Q-,4+9K=A***OVB4^4*,;5?W)IGT?C4?[G)^U/HMRG^O\<*[^ ^]=9K1^0
M1YM N_I>[8]'L9KC2>JJ4+*ZO #'D$>9R;FJJZ##*;KPIO)J;X4ODNK3!U!W
M6D"Q9WP)Z=-X? .J?])6@2*V^H(];4QCTMS4MOM9G$M+?TYC\32^<RZTE7TX
M](=*6>%QQ3=X;!)_4XR13[D)WQO"VYGV!JA-G1/>_I3V#CS2_VH_H2QUQ"?Y
M?P6^TMDKTD_.*H^URW8 /_JZNF^??6ZOYGB2NBJ4,)%5X"FHY"#*N5/X)E_!
M[ >'ZGJ@8VM<6A#*">JJ/L[.?&QWO,JHCW/C2S2&1.TB]:^R"@)@+%Z?[U5?
M, 5MLIJWM^U^%N?2LMUI+)[&3\H+S5_MT3;E'?+/S:]\-AY7BA]^>NQF')&7
ML>;D/E2L:Z_*]KV9;68\D^]C>A<>X7_.F/2WH[/$^13_K]"ZY+GOZY"0C]_$
MU(; E]H/@*VV\?M6/_<F8T&<I*X*)>><EL',-W54CY^KBU:!*V4@J[Z4 :R^
M?'Q>'ODBP=;XDFEC"6U2#XZ<C_L%5"?G(7QLDS07M>/IU%7PII_A7)H.];T/
M&O#U4?\: ]"V\E&V5\J$QQ6:]HOO%;Z=5:Q[FWDN*/ZE;!,\GJ?\=^$>_L\V
M5V<NK,[=3_'_BKQ?\CPE+?WJY='TF*$=/[>%ZDSK_T@8P\1)ZJK0/<%ID^/*
M>T#@=WW+K?C*I=4X_#KU?WD%7O9!TPOO?>"P\[74OW#S7[ZE/!K^%=ISYGG4
M_^66O-R#QG^=._W*JQP/UE%K*O4Q4UX!?H7>6'P>]7^Y)=PM$T][T)122BFE
M7$H?-*644DHY/'W0E%)**>7P]$%32BFEE,/3!TTII912#L_N!TU555555=4K
M:Z*_H2FEE%+*8>B#II122BF'IP^:4DHII1R>/FA**:64<GCZH"FEE%+*X>F#
MII122BF'IP^:4LK;P5]P[A\]?![U?WD&=WO0^%]8W@ME?_SQQU^_V1#??__]
MK]^W@,WUU;_>[>-+2-=\)_%79<^5F_Z,_G???7=2!GLOE&?.TU^[EO+089SJ
M0_4N.9ANX6?ZE[_PB;X3XF.K+XV_? [$G\=WGB&Y%\[M)R^;FF*/_E9GQ"=P
M:_\GY^Z%^O^GT:=Y[TQWS19^)@O25FM(VC/6@?%,?/E!P^0)+NKNG=@E92]!
MFVSK\MO#UO@4,.?8*D>Z!TW:0"#NZ<<WM@X1_.#(+ZLYK>JMN)6?<_-@YQCH
MYUQ?VG#E,U"\$L_L$V*&?:##V_,%^=.!O 5MY+Z$2\^[=^/>_J<>]:DS\>G^
MU_F;_I3?_*S$UKJ<@W*4]Y@G3>O M[>E]7\&C'/B)'55: N<B@-\XN>@GWL$
MXZTNVJWQ*6C.L54.?RD8M\IMC0.8KP>U#A+2DZU^MNI-W,K/BAW!&#V&E$?:
MJB_BCGJYN<O[XON']2<>%9,PQ<.E,3Z=9VI#VMJ;[\R]_4\YZM?_WX*_-?_T
M,7G(P4>4/8?6CS;]3&8-9.>Z\KTZE^_-:DXGJ7LF[L@)3,J_$R9.'L(Y_%0P
M^L$Q.3_39$M:0/4OJ7WP] P"V!I?,HUQ8JN<'P@JMV>C)\S=@^_<H>'S\C%D
M/=8C-X;2ON)GVE ^;5'&QP_D90Q1;XHK^M8XI_[*>^*QJY@\Q[F]X2C&LRQ]
M*5[)]]C_).[I?YTSB&_GT_TO'X*OP1;X2'6VD#_S3&8-9"M?WZS'LUC-Z21U
MS\2=##HFFY/,-,K+>>!M3,[W-!TT?KEY6ZM\7R"^U1Z<&U\RC7%B54Y!Z6-B
M#*2A]-\6E/<#XMRAX<')3P5GUJ-<CL/3KO$S]9&@K:P#/D9!FO<E2*<-2?,I
M[XWB%1$#JWAW,AZWH$VT!6VMSHAWYU[^QY_:PYP/6VOPR?X'_+GGO-L3R_A:
M9SMM^OGKZ^#ESJWEO5GU?Y)ZZ2 SJ#)H=?$YV@RJYPXC+<M[VG21.IG/>*;%
M9-%H=\_X$HUG);%5S@-&3.6G<F+RA<9.W@2^4)O\U(;(>I13X I/N]3/:M_'
M"J3E'#T>!';63?9L[O)>L.;$D+2*$<7K:D\[BM75'A)[VWMG;NG_]/MT#CCG
MVGMW_/Q>09FM=0%\2!E!FWDF:YW5'_DJ0[KG/0H?LW.2NBHTD8X !:4";>5T
M+W/)@P8HBXTRX/.BI6V536E1SHTOF<8XL;?<"LUS-0[-U<E#(:%-!:+//>M1
M3H\7X6F7^GGE"_K7> 1VKBNV^N)GYL.C-U1Y#8@]XI'U)\84)T*QFO&\PO?%
M%K2YVIN?Q*W\SY[VLX#RTSX7G^[_<W%*_AX?488U$K3IZS!!'6"-M*ZLU;DU
MOB4:0W*2NBHTP00H/TF!N'(Z9>1H#]SIXIO20.E(CM3F\8MVR\E[QI>LQI/L
M+;?%5I!HK@[S)LT#U/%Y^=RSWM2OIUWJYY4OILV#K7A8L=57^2R(!<6MQS<H
M3C/&MMC:<T[V]:G<PO\Z?U;2.>.0_LG^]_,[(0__:%U6Z%R>M&J;]9;?*:/O
M/>?V+6&,$R>IJT+)UL4I9U)& >VHKAR!@^2(J;S:6T$[<K[J:P-L+3KL&5]"
M^M9XQ-YR6P<HZ:N\G"MH[.0E.1[W3=:;^J6LTB[UL]KWL0)IU'7HXY$;HQP/
MCT]^*FZ))^U;Q7O&USF\C2WVEGM'[NE_0;M;Y\ G^Q]69RY^PS?3'; 'VERM
M&>>W]\FWUH ZAWW0X+35!:;+2TZAG$^4;P]&#US5]4#%UKBT2?QBI*[JYT4+
MV/0A5$9]G!M?HC&<8V\YC2>#:)I+0KX'KOSG:9!S!M\068\\;*&YR(_3V#P?
MLD_\ZC%#6?)SWI3+M%(<Q18_B2/]),WS/=[WH'VPM>?$->V_"_?ROT-[?BXG
MG^Q_\/-;Z-S>$[\K:'-U_K(F[G-L!*R5OA^!8BTY25T52BBW=>GDY<4W=52/
MGW),!B[I*JMR_!2J+V70JR\?GY=';#AG:WQ)CB^E\>2XSY'M[*GK 04ZD"?E
MG)FGUDCUO SS4%VMD?=UC9^S3=KP^I=<*.6ST:7I$L16YDG:UQ[_0FWNP=OZ
M1.[A?T=GS@IOZQ.9_*<S>9+.U#QSDU4^OI[60WWF6.X-?4Z<I*X*W1,"%Y7+
MX5!Y="#=D]6F*64%9T<^G,OCJ/_+,WC9!TW^R[]<!OY[EW^I\#CKX5A**66+
MEWO0^*\L^Y\8KN==_C--?U-72BEE#R_WH"FEE%)*N90^:$HII91R>/J@*:64
M4LKAZ8.FE%)**8>G#YI22BFE')[=#YJJJJJJJJI7UD1_)5-**:64P],'32FE
ME%(.3Q\TI9122CD\?="44DHIY?#T05-**:64@_/++_\?><;MG8K<$[
(245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>a1q24regionalsalesresultsv2.jpg
<TEXT>
begin 644 a1q24regionalsalesresultsv2.jpg
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M-?F,[XY?P?K^4#W;=].8YSWY)37S^2@]1G[GRK7&^VI[SSG=]Y7GS5+.NX#
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M$"(B(B(B(N)1SC(L9 $       ".@D(6        +@6%+        %P*"ED
M      "X%!2R        <"DH9 $      .!24,@"      # I:"0!0
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M2P_>F3D#?\3YMC2FHAMWG;=6R.ISC2&<&^7V6@YUN9UQ!X!S,Y/GW3-X]./
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M71/B!@   &>%0A8        N!84L        7 H*60       +@4%+(
M  !P*2AD 0      X%)0R (      ,"EV*60141$1$1$1#S26?A%%@
M )X.A2P       !<"@I9        N!04L@       ' I*&0!      #@4E#(
M @      P*6@D 4      (!+02$+        EX)"%@       "[%H87LIT^?
MOG_\^/'GUAQ?OW[]_NW;MY];S^7+ER\__NI^]+UU;T>A<=/X 3P#S3_->?GA
MPX>?>WMTW&VKF3-K?6J^+QV',1I;KU?)Y\^?__^8RBUKJV*PM.:I[VZ-RCC*
M[KY@&QI3C;>Y)U<4#YV7:/LLSUWX(S6O:VZMH?S-]IG/?J^!\[%GOG?KN/HA
MW\_#(_-<GU_M?6IF3$S;<DL'"H8"-(N#<88$TWT\\P5,XZ;Q S@:S;U<^)0'
MMSP\<_YJ.]<"?<YM/;3S&CIWZS7?%8UCMUYI.]=K%[4S:.S5MKX &?=5UZ@:
M-Z_ISUQ+KX[&;J]<<?%2Y\$KONQ<'<4Y\VMKW!UKY[!S,7.ZSBUX/GOFN]K5
MF OR_3P<D>?U&E='WV^6MN66#C1P6Q9)!X!"ED(6GD.W" K-Q]E\J NQSJOK
MAA=?YWK-M[HXPZ]XC&R-CV*@6"3:MQ1'Q]]VXZ\^?+RN45W_6Y\#\'LTIAD'
MC?NMN:(X.'Z5+3D.CT<Q\OHH:MS%4MR[O--VE[,S<P>.88]\US&UL5U;\OT<
M*#Y'Y'F]SI71=YEE]T)6">J77/4C_:)5$\^!=-+:&C#MTW5\W.UUOO=Y.U$_
M>5R:W*>^NX5#]YWMLG]_QVRC[:1^7^FQ$-U$!'@TGI<5S<69^9CY9W1>S=LU
MNIR#WZ-Q]9I1QUQTX[<61\5)_8S&7\<<R]DUZI;XPV]H_.NSHS*;*WXN*89J
M7\G8PG.IL7",]3=1FWQO6*/+69T_D\?P>/;*=\5Y:1T7Y/OS.3+/M;VECS/3
M/;]&M"VW=%!?8)2@&20E5R:9MWW<056PC?K,1-?QFOC:)XW.SW[K?0D=S\!K
MV]?U??@^-1FR?]^WV_MX3AK=H_NO_0F?XWOL)B+ HZDY:&;GH]K4?-2YFM\Z
MIKYE;5/1.35'88S&--=)KS$UCHK#S+AV:U1E=DZHGUP+81Z-[]H8S^1*S@<_
M#RNC.0/'HWAFSGA=KLS,#U/?@\RH;SB>O?+=.*>[=9Q\?SY'YKGVK[UW784M
MZU7;<DL'&OA,N"SFC/;Y!<Q!= !&P5,;)Z8^UY>DT3Z?TR6N[C.OI?:^+R=\
M7M/'C*[G2:+/:I-HG\>BNW[][O5^ (Y"\SCSU@OCS'SL<D-]U?W:URVJSAWI
M?(-UZOC6]<3D.K5$7?,Z9M:H49QA#HV=8M:Q)5>R'^=SA_;7_(7CJ7$8Q4SY
MEVMUAW-9=ODZD^MP#'OENUF+K8Z1[\^CCO\C\UQS0,?4[NIT8S2B;;FE@SKX
M79+FOCK0.E?;G0Y^?C:S^W)AD'FOV3X7@]'"H+;:+]2OOE?2[1,Z)W6_NI=N
M,@(<@>:JYZ3FH5TB<R 9S66UK3F9Z'A=+Z"GCJ77J?K0TGCF.C=BM,XE:VN4
MCG?W /,H#Y=RQ"SE2HWY*$_%[/7@L=3<T^<N9C/K<J*VH_>0I5R'8]@CWY.U
M=9Q\?RY'YOGHG>"*=&,THFVYI0,-9CY -; U^7*?@^B!UKEKR:KV-1'7]JE/
M;4NC:^6]9OM<#$8+@]JZ/_5?)U'=I[:R?G?WJWO9,G$!'LE,+M9\-Z-SE0\U
M3Q.=T_4'OZ*UHUOSZCJE&,VL*Z-U+EE:HW1,Y\-]K.6(6<H5]:%8=-:^9Z\'
MCT6QR=QS/OK=R(S6UA&C?NKUX#GLD>_)VCI.OC^7(_-\U/<5T?>8I6VYI8/Z
M8JNDJ<'(?0IH#O3HQ3A1^YJ(:_NZX[J/O%:V\03PA.O.UW=0'_6S63NN_O(:
MNI>9%TZ O<EY*.K\'Z$Y[5Q.M*_+8_<YZG\F_^$W-'[=FE;C,8I192;FHS5*
MU]"Y<#\U7GODBI\U'=T\@N/IXC"[SW3YJ7FC<S2/S.SZ#H]G[WQ?B^W2_(''
MTXW_[#XSF^?=OJNB[S'+TPM9)V&>HV!JGQ-3G[=.A'H?ND\=SWO-]G4QT+G:
M]GWZOMU>QW6-)/>IG=H;]Y_7Z"8GP!%H[F4NU.T1.7\K.I8YI_XR1^JV<VK4
M'_P>C55=\[S.>)WRNC5#7?,Z%+.Z1M4XPGUH?-?&>&NNU.>/<<P]7^!Y*,:Y
M7HJ:OYH72[GF..>\4/LZGSQ_X/GLG>]+ZSCY_GR.S'.U6^KG2N3XK-&VW-*!
M!E*!,AK$&K2Z3]NZAO<YV=),/&TK0,G:/B\$5O?931YMZ_Z[Q<#M;5Y/Q^J$
MJ?O4;Y[O:_A[ZWB=B !'X3R4F<.BF]^>OYF;E>RSGB^<<W;F00V_H?&J:YZH
MZU3&Q^M@%S/'<RD&=8WR.9U=O&$=QZBRE"M+<16:)UV?FBLUU^$Y*$8S:V32
MQ=5SP7;O%-K7[8?CV3O?E]9Q\OWYW)+GW?O73)XKUCKW%:ACLD3;<DL' /":
M\.+S&NC!-BIXX!SHI:5[$=T;O>AT_Q@"ST'O6D?DYE'S"^8@W]^+H_+\J.L<
M 84L -P-_Y+[&A#'\Z.7S4?'22_.W2\#\#STCTR/_@?#(^86;(-\?R^.R/,C
MKG$D%+( <!=ZT/(ON=='_SK++^O70"^VC_S/PO1<YU>Y\Z%BXU%KK?)?<7^5
M7VE>"?+]O7ADGBO.KU:W;?D^%+(       #P="AD 0      X%)0R (
M ,"EH) %      " 2T$A"P       )>"0A8        NQ2Z%+"(B(B(B(N*1
MSL(OL@       /!T*&0!      #@4E#( @      P*6@D 4      (!+02$+
M        EX)"%@       "X%A2P       !<"@I9        N!04L@
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MVXJ.Y1SHJ.N\J'-'N-UH_L YJ+'L4!NOV5W\7PU]OUG:EELZ,#JG2TXOQ-V
M^T%N<_'M7H:Z?7F^CM=^?(U$?=1[59N\1_<EW3X7"4^DE,4"SH)?:%*3<[NJ
M8Y4N[SS_ZPM3]E7/$<JA;%/7A7K?W9KRRNP1M]I'CO%,W&1=RS)N75R3;K[
MK^1X5XT^UQRI.=0]=Q2#+G=\3GWAA?.P%%_-!>U+O,_6W(9SX?5Y1'W7%#ZG
MYGK&O<MIK0/D^OE1_'*=[YZA?G;;?.:_(OJ.L[0MMW0  .=%#\5'O=AHX>6E
MZ3$0-P" UT1%RA%KL(K8+)  K@*%+  \'!5;W:]!<&Z(&P# \U!Q^>A?2E4H
M\U_&P%6AD 6 A\-_LG1-B!L P'/1.OS(_SQ4[_'\ES=P52AD 0      X%)0
MR (      ,"EH) %      " 2T$A"P       )>"0A8        N!84L
M    7(I="EE$1$1$1$3$(YV%GUX!      #@4E#( @      P*6@D 4
M (!+02$+        EX)"%@       "X%A2P       !<"@I9        N!04
LL@       ' I*&0!      #@0GS__O\ N642?5-,U-T     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>a1q24segmentsalesperforman.jpg
<TEXT>
begin 644 a1q24segmentsalesperforman.jpg
MB5!.1PT*&@H    -24A$4@   ZT   "E" 8   "W'ALO     7-21T( KLX<
MZ0    1G04U!  "QCPO\804    )<$A9<P  $G0  !)T =YF'W@  "S#241!
M5'A>[9S-RB1+5X6_VU '"GT)(@YUU@-!\ )4<"#T%8CBP&GC2$2=.1(:1 0G
MSARUB#?1 T'P,EI6?[W.6;5[1V16U5M5D57/ XNJC+_,C!U[1^RW^IQ?? 4
M      !8%))6        6!:25@       %@6DE8       !8%I)6
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MH9IQDK3ZKPL((8000@@AA-"]-..'I!4       #@7I"T @      P+*0M (
M     ,"RD+0"      # LI"T @      P+*0M (      ,"RD+0"      #
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M>^M?0/WK+,!*D+0"P-T8_1-$. [8$ #@L>A7T%O^,VXEQ?R!&5:#I!4
M  "6A:05        EH6D%0       ):%I!4       "6A:05        EN7L
MI!4AA!!"""&$$+JG9O!+*P       #P,DE8       !8%I)6        6!:2
M5@       %@6DE8       !8%I)6        6!:25@       %@6DE8
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MQ%_6 0#61GOM+?=;)<7W^#47X!Q(6@$      &!92%H!      !@64A: 0
M    8%E(6@$      &!92%H!      !@64A: 0      8%G.3EH10@@AA!!"
M"*%[:@:_M (      ,##(&D%      " 92%I!0      @&4A:04      (!E
M(6D%      " 92%I!0      @&4A:04      (!E(6D%      " 92%I!0
M    @&4A:06 $SY^_/CUTZ=/WZ_@B'SX\.'KY\^?OU\!    ')N;)*WOW[__
MIHH.4AJC'J9T0+XF(=8A^]V[=]^O?N3+ER_M??>@?K,#O-ZI>U> HV$_L3J?
M4EFV49\16_5&_N/Q.E^2W[I>JOY8G_N5$^XZ5]U\9KU4V9KOCK1AMVX4HW/,
MV;K8BN?0XWW4TMZTA?=DJ9OSM&M%=;(5K,>672LUAF+7]9&-.A]7_-X;/V=Q
M6]>7G)GA=CC&;W'.?GLTMM[_I';/9(G1Q,H)I!H0KTW\--[,21V0;^& USX[
MP"K(1^1+DGRXKFWY6&Z2#HQ=0%3YJ"ZI]]#WO+;O.G%R0I6^G/6U_2N1[ZYY
MU1QI+M-FJL_XJSJ5&8_A^>WFNZ(Q,OY6&]9UXGOX.O']9O$<?D0VKW.JZ[1]
M17;)>:YVS'I]3YMZ;<%Z;-FU8G]4/R/;YC6LA?ROL^DY\5-MTH?U/:^]+F -
M;(\MFW@O,/+C9[+CUKN<U.Y]<4]N'G14)B>IFY]P^:6H[\Q)N^=Y*[0AU/<!
M.!H9Z.1/NK;?Z#._)]5W/8Y5VR<>,_W2FZ[[=?%"/N?#>.?[K^J3.1>: \VE
MYU/D]T1ELIOHYB[GNZ/:L*X5?<\U(G3=C:GGMV _G8WJX:62=A?5'W/,NG:T
M1M+FL Y;=JW(QM7?W ?61/Z7-A:RHVPF;<7/+C;4N"TT9HW=\!AD<]EURR_5
MIMI,976]')6M]S^IW6J<U(GS(<6;GQVC"ZCI?+5.XZ3Q[%2Z3K*_ZCV.^JJ/
MZ>[O>PC5I;$]EJ1[:BRW%1[/RCJ 5<E-3&M\;X"K?JYK^9*D\7(#W$/ME[YH
MY'/IPY7JDZ^"YLIQ4'.0,6V&YMOVUKRE/87J:GQ-U#_OY1AH&]9ZT8UIN^5[
MP.6D3^_!=K.MTL_LE_[.OG8<JETK:>=DU@<>A^V99-F>^.E8NX7L3RQ^/+;I
MGIC>^>W(QX_(YOM___S&5N.D3I(<Q!/IR1?U\*(^>6TCN:^,IVOW%]5)5:\R
MHSJ/48WNZ]K>X^>]?&_COG9^!PZW%_5] %9%:]?K.=?P"/F3VM< *5PGGS@'
M^4K&C>I3'G?T?+-G>G8\5U+&VQF.8;93QC[C.1U18YSNG=?J6\>L,3OO4>O@
M,F0'[TU[J.W3#OKN.I6=Z]?P.+;6@?RWUCN6O&(<79WTQ8X]\5/]U4ZVEYVE
M41_6P6.Q+^K3^_6(;)MLK9DC,7M_<5*[U3C1Y*839%\YB@^F^7T4*%7O"=?D
MU^=()ZWW%3X0Z;/>P_?W^-7H^NX#E\:MAR_U<]]\ER3O![ R6LM:K]9LW:J^
M6^_"/E>#YPB-XWO6/O9):_1,KK<_OBJ*4SE?(QMX7A4_C:YKC-MCR[1?G7_7
M&=^W[@^^;\9SN SODS.;&;>5JF]E/!"RD7T^UQFLQ\RNB?T[_=YVG_6#QR#;
MC/9=L2=^VK[5YET_E6E,> PY_[*7[#9BM%?O61-'8?;^XJ1VJW'B@XD^-=%R
M"*-K3Z ^[3A[)KR;_"R3,^>]A)_% 5CU7@2^G]^MCJ]R/5\=P^3]]*DVG?R.
M *LC'[#/:NUV!Q>55S],1KZ\A?W,_J)GT76BZZU-N_9Y-30_LH%LU-G!\UQC
MI=K76&5;CE"=XZGP_.<]]3PJDWP/KQ_5I3W5?[:V8([G_Y(]I]JR(KO(KFKC
MM2/;U74$:[%E5_NXY6M]PEK(UV:V5-U6_-08&7.-;%[CQM;]X'9DG!6RC6PT
MPOMZW>_K.$=F]O[BI':K<463I$F6<^2BSXG-"7:@[";<3IC?399U&ZCOXP!L
M ^K:;?VL^LQG53^5US%,WJ_V!3@B6L/>N.17=4W+#[SF1XQ\>0_R*6^HNK^?
MQ7CL&9VOOA*:/[^_YB+GT+',<YQT,4Q]:\PUH[JM6*@ZKR$]RTBO;,-+T+Q>
M,V]IEXKJ;-.T[VQ]P!K,[-KA&'%)_(;;LB>V;OGC:(QNO]VZ']P.V2/WPU2U
MDU%=C?]YICHZ>K\95R6M6NB:*$U\#7XJ<YUQH.PFW &W<\@LZS90C9?C^EK]
M[(Q^UGI_77MQ:-S.H?UL^9P 1T+K/WTLU[Q]Q/ZY9XW;QV:'GE$;C2]?$GE_
MXWZB\[E1''EV-!>>-WWZ_347MJ?GSNTJW7QV94;CVA:)VMMN^=UT=C4JKS$<
MMI&=]J[[/7MM)>V<-M4:P%YK<(E=._OA@^LB.\J>(_;83FVZ]="M'8UE7X?'
M,MIOD\Y>SV3#K?<_J=UJ7/$!J7,@;[#5^5QN;"0[4N>0M:R.J[H<0]0R!_LZ
MMLKT#$+WT;4/V7XV.[_'R,51GQ]@1;QVM5ZU?OV9ZUW?9YME8M]WWQ'RM]P\
M[2_N5Y]!Y'/X/NIG-%ZW(3\[G@M]:G[\J3)A&V=\JKB-YS/''*'Z7!?59KXV
M];JB^AJ'84Z=\SW(1W*>9[;6^)+1=_N8;/^*_K8JY]A55)^OU[ 6Z7L=JM\3
M/V7C].FZ;LQL[<!]\?EHAMN,]M^CL_4N)[67O+CZY('&>&*[P.B#EI4.TSED
M5Y;];;0<)P]S1F/49U6;?$:/);E]!A '_-0Y!PF 1S%;N_;73IU_^Z!4U[Y\
M1CZ4R']RO-HG?4ZJ]ZO//=O0GQW/>\K4>4RE3>H8-4:/RE+5AHZWU@P]2XWG
M,$?SE?.;LBWD%]5WJEURCS0JZ^R1?@MK,;.K_3M]=,OG81V\W]48:[KXZ3[5
MOS-N=#ZN=="5PV/P.2R1?7+_%G6O'ZV5(U+?OW)2N]48 (Z/ MZM#BT*GC7
MPMNC0VL]H+P5&I=#+0# 8] ?C.X1@[6/L%_#2I"T L#=T$9+PG-L=(BY54(,
M  !S%']O_0NH?YT%6 F25@"X&Z_\3W>?!6P( /!8]"NH="N4%/,'9E@-DE8
M      !8%I)6        6!:25@       %@6DE8       !8%I)6
M6!:25@       %B6LY-6A!!"""&$$$+HGIK!3ZL       "P+"2M
ML"PDK0       + L)*T       "P*%^__C^V ^67(>.WX     !)14Y$KD)@
!@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
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M[4A +5M!X#0GQV;6U2@ ZPM695H22>^WFBA"XQ/[<S5WA!6OJ*+'+(TZ]SC
MTJFKR0E:C4H#)P&M#<3+&LX)1.F85K+TMU:X=+ZYO%CY93-,N3\LK[FZ=36M
M:&G#=0&P%F7E2HV?WV]8E6E)Y,$?VSB"O)YS/77W<2M>4445Q:@"6&-< :R*
M*G(*\L<1#S_PM_@"<:(5#.)D'4#C OBHGB[WVH&:>QF_K]'?Q-F%G-\@L)6N
M*Z"V92P&K]?M-NMRVE %L,:X E@55520*H UQA7 JJ@BYY;7W&=U2R]9F6IF
M U=S^FONI58\2$NZW"L 4[?Z\JDV!+)TBXD)^KM6?-I0!;#&N )8%554D"J
M-<85P*KHL4Y],]Q>0W6W+I0+=*MP$'"U>*;;T8IG4M^.;N90S=T=6LG2RA@
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M@WSG.83^@X^R)^PGYKK[F<HBVX>E-_41*IO'2FRR)PY;ZCMPNA(C40U(3PJ
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M]/XNQGRC)>D@*TEAIS7$P3.L6D=$.X?('[/\6BS=:*S2N?*'Y%",R9;(LQC
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M-3=RVXKZF0#+$EMIM"QB?+\./0V4L _:C*1!_4R 92#G>BM>B@ F'\FZTC"
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M^/$L)OKH!YE%U#E?.DBWD["=^V,6("A*JW?R7V_OR4H:WAXU]UFK,DZ<GUX
M*^"W?GP<8P(-OE Q(>E:/JGZ,=]J9OD.Y>X$F&4^08FOO5_)-0%N^K5D&WTW
M4C-A-SVI=P"3Y>?)EU>/Y\J9OO^?6K&VJ!. )> NWXCE2K'799=[GU7IB,B5
MQV;E%(V!L?0-!VX5H>L*8 4X#V")\)%=\+GY67--&9;_*U?J5B* X?I%.5\T
MP*8_S<J5?CZNNYO;W:O93/H<#FU%L8/TZ/=%!Y[.GQ( BW^.YL!5"+I4A16
M4K8&I$)F\.]:NVU1)P"+P;]<YV-)0S*J7<J]S:IT1 *86<'EKPY!U*&D@9XJ
M@!5@2TB9 $NTM-OMA3WGZ>HL:Y(HPY))>L>WAY;4W)NMJQ8B#J[,2AI>/QV\
MG+&95G(Q0YM+#:RWL&26S@"%+>\ X_RT 5@]W>X5M-6R?T+MT\_Z(E]=T%.C
MU+DBR_>;V:^"UMSLK*1)N?_2WJ'$7Y5HM0UA2\8[TT:=>SSM?@39K\)'EX1R
MI0&&MM[RGU!' *OA7B0Y\@ 6XSC8JG1$Z._(K)RB7(F=AP3\K,HX(4,%L )L
M\VTFP!+IUAEVOF?2<R6RC=3="@#$NZRK%J+O"[)RI6*"W^MFM;D?MIFT 1U]
M9'[OUE;S6E:?IPK \F]QU0!"AIH" &MOG8\YD0:B0,;HI=^J&R+T\86LX#*
M-3C<Y7:S*N.$GBJ %6!+2+D 2[1XIOO'H9H[3[XB?6DRCK5;E!F7!QZ XE6
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M9!ON4BM:BJB_[U#-K5)R1-9@^PG+'U0.?8\#"L5W$J/ZN#E :V11Q@?<$S*
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M]HOU+2VK,H&T21(9[O()+%!?[1+H6WJZW6NL2EN$PC)!B Q-T%]LQ5N(,50
M*\"6D(( 2U?2..OSAPARRNI)P8<EYV;)$YE$BM"#8RM2P:=/+/FV "Q V>%9
MP>S/1?;?%27=DL*7Y_O@#O0A7T:/2G8OMBH3B#+3 F 1)U_/ B-FE^5:.;0J
M;1'^\]>,]]=%099R#9/K@M$VGG!B[ ?+;DJ>H;8M5RXHHI\8]37<BS2.G%PI
MO^ZR*A,(?3P!&6[* O!J [U'7[I;A !8!V7E$\48$]?OK7@+H<L*8 4X#V!I
M&P3Q>:A\?J#A'I+/X<NCG<Q]>G"']A:&5J0,8+7<P5(L9(W#]'^5%6^+%-M<
M#-R=E2N5JWK!%U9E DT)@&6K2]&DJ@8XOZ9WI_PG;6*DO55Y$S!.%04N(F0X
M(2N)>B3;F'C;IRPAPP7:FQ%J7PK3&'#JEH]*)D3]"F %V =;"F#I*1?.?9D@
M^1/G_+NN5$Y!+EWK;YRXK02;$.W>++F:99&,:IODW?)0A#9EXF>]H40C]BN8
M==>_,/#8>5%B3/L24YMB$ZC9X3J22_"3/)29+BM81YA/!ML2^W=:-=PI5J5M
M0J=/8L*\.FN?9C,KL2XGUI7 K8E"I!R(;C-7XI%C;<].[>\]P2\_(/EB(,[\
MXP]6/$@"#YEY2&VD;ON4)63X62Q7RN:R?4\C_NH<_*,"6 $. :Q1   @X+_Q
MN^OI=XUD4QN)G^AO='6<%6^+Z'MV*%?*1LC3\E"$-LWC0XMCX,?OC:JYD<&&
MV\6JE";=T2)/;HC%FY>WYF[11855F4!3 F AW%]AG%O3RDU82K;)L_22>D*T
M\XM8\DN,N*PK^S4+>K$G @^%5B3$4A:.,%]/'5J54B1'H'YPWXY8.@!-SV5R
MC6Z*I7X%L )L"6D"P.(*VK^S9Y0Q*8#2=54'>U]@Q=LBZL])^[7ZD1Z0)_BR
M16S\S9B>55=?HI<NK7AI6MYPWXKYB-KW?I;QIFW*38\5K"[W LINB"4@L<[1
MU]KT$YWM$ FO1E*[W?PXV%_"TK,NULA[I9[X$^BE_G7J(]UFPAXTI!Z@*$/H
M[)RL'&*^.6'3<9K0O3X^W1.;_'0!@9\O#KW+KPCUSG#=M-\;R\7>!\G%6:\T
MH7X%L (< EBZ\*._E<J5 B[INEZ/':ZLH^L_Q'*E5O:MV 0BSWPEMDJ=Z)DR
M+1]A+DK4/24K5]JXH_/IE !8(H3]3-;D[3_,RA6B+UR2M%\)9Q[0/?E0VPI2
MC#L"6LU%NGD&72LYZ^Z#5KP44>]+6:M7<A9DS'R9*8%1 :P 6T*: +#TPD[.
MW9X.ZH3E%^B]K]U]6"2CO\.F\]*3C(&Y];3]/"LZ@;2BR[FAV"J6Y$5/M[4#
M8/09(-J.?AG>]'3+O-W<$ZU*"U%N6@ L_Z'FFONS_"K4EIB^O#Z'2'(DK*=;
MU;9)MX6':^Z>F.V:62N( LLDUY9W[V418SHJEB?$YA]M/7 CD$@;T0<ME$,'
MQC[WU/)F]#0AY^>5+T(QJ6,:._UE?FP[1M3[M":W6-LZAUZ#3X0GA!]5 "O
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MDV+\S>=*_'%?^9INVUNU;4+(TX!?[O-US7TXD4LYG#R@7/F2HJO&TX.<^[^
3LA^];2SWH0    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140027261712672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Apr. 16, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 16,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Johnson & Johnson<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-3215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-1024240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Johnson & Johnson Plaza<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Brunswick<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">524-0400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000200406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, Par Value $1.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes Due May 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.650% Notes Due May 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24C<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes Due November 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">5.50% Notes Due November 2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24BP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes Due November 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.150% Notes Due November 2028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes Due May 2035</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.650% Notes Due May 2035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M1S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ #&*06)>*NQS
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M7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @ #&*06"0>FZ*M
M^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E
M #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&
M:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T
M==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)
M(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    (  QBD%AED'F2
M&0$  ,\#   3    6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N
M+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78
ME!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')O
MJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<
M^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!G
MZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.
M6X.^D<WC_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L!
M A0#%     @ #&*06 =!36*!    L0   !               ( !     &1O
M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  ,8I!8);/_AN\    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  ,
M8I!8F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    (  QBD%CB%M3@?04  )$>   8
M  " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  ,
M8I!8GZ ;\+$"  #B#   #0              @ '!#0  >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    (  QBD%B7BKL<P    !,"   +              "  9T0
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (  QBD%BJQ"(6,P$  "("   /
M          "  881  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  ,8I!8
M)!Z;HJT   #X 0  &@              @ 'F$@  >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    "  ,8I!899!YDAD!  #/ P  $P
M        @ '+$P  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"
(   5%0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>6</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>5</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="jnj-20240416.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K/A" isOnlyDei="true" isUsgaap="true" original="jnj-20240416.htm">jnj-20240416.htm</File>
    <File>jnj-20240416.xsd</File>
    <File>jnj-20240416_def.xml</File>
    <File>jnj-20240416_lab.xml</File>
    <File>jnj-20240416_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="34">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "jnj-20240416.htm": {
   "nsprefix": "jnj",
   "nsuri": "http://www.jnj.com/20240416",
   "dts": {
    "inline": {
     "local": [
      "jnj-20240416.htm"
     ]
    },
    "schema": {
     "local": [
      "jnj-20240416.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "jnj-20240416_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "jnj-20240416_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "jnj-20240416_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 4,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 6,
   "entityCount": 1,
   "segmentCount": 5,
   "elementCount": 32,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 34
   },
   "report": {
    "R1": {
     "role": "http://www.jnj.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20240416.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "jnj-20240416.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "jnj_A0.650NotesDue2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20240416",
     "localname": "A0.650NotesDue2024Member",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.650% Notes Due May 2024",
        "label": "0.650% Notes Due 2024 [Member]",
        "documentation": "0.650% Notes Due 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A1.150NotesDue2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20240416",
     "localname": "A1.150NotesDue2028Member",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.150% Notes Due November 2028",
        "label": "1.150% Notes Due 2028 [Member]",
        "documentation": "1.150% Notes Due 2028 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A1.650NotesDue2035Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20240416",
     "localname": "A1.650NotesDue2035Member",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.650% Notes Due May 2035",
        "label": "1.650% Notes Due 2035 [Member]",
        "documentation": "1.650% Notes Due 2035 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "jnj_A5.50NotesDue2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.jnj.com/20240416",
     "localname": "A5.50NotesDue2024Member",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.50% Notes Due November 2024",
        "label": "5.50% Notes Due 2024 [Member]",
        "documentation": "5.50% Notes Due 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, Par Value $1.00",
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0000200406-24-000036-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000200406-24-000036-xbrl.zip
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M/D(?$N2/FS#NJ@@ZQE%T0-PP'<-H51J@0= 3W$]Z+JH<J5D:RJ^IR(8( A_
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M*(<_ WYP!R7U74J%Z.,6EP^^_L8->6($U>L;!,U%$!^'"#+[<:K N0;#+-L
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M>VSKU/=3JH^"!2'B5 %9*)79'[Y:1+ZBA2P[P^4(V$=>NJ5:PTO&"Q9F"JD
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M#MO^MGH:J9AQEBE (8. 2(R X)( !A.(*<$B%/3QY=.4H0AG"0.,PP00$2/
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M%":S-;=M#:S>U.IZM8B53%222A#R. 8$AAP($F&0D11B@:)8BG!1/WRS%ZH
MOWW:.M$@V<"<.;"L>]1:J55Y6\EUGM/0)L>OO7F^!@YVD(//!CMHP/_[T_EW
M;[T#M9R)_G(6YJ7<0UB:=%Y6A\1*:4GLNTA6FEG#:J7DD\ORZ[DVH-GAT+P
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M_Y.M7<2F/]:Z9_7'/-/:1:SW@=;.P;ZR_*@N<_.H4%$WQ\-D$J80QQ0(F$:
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M.3$Q+FAT;5!+ 0(4 Q0    (  QBD%@U\F&RSP\  .V#   0
M  "  =P@  !J;FHM,C R-# T,38N:'1M4$L! A0#%     @ #&*06).1L1!(
M P  !0T  !               ( !V3   &IN:BTR,#(T,#0Q-BYX<V102P$"
M% ,4    "  ,8I!8*E"TLN (  !)00  %               @ %/-   :FYJ
M+3(P,C0P-#$V7V1E9BYX;6Q02P$"% ,4    "  ,8I!8:K77*/4-  "3>
M%               @ %A/0  :FYJ+3(P,C0P-#$V7VQA8BYX;6Q02P$"% ,4
M    "  ,8I!83=]3WI8(  "81   %               @ &(2P  :FYJ+3(P
D,C0P-#$V7W!R92YX;6Q02P4&      8 !@"& 0  4%0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>jnj-20240416_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:jnj="http://www.jnj.com/20240416"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="jnj-20240416.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2024-04-16</startDate>
            <endDate>2024-04-16</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-16</startDate>
            <endDate>2024-04-16</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-16</startDate>
            <endDate>2024-04-16</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-16</startDate>
            <endDate>2024-04-16</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-16</startDate>
            <endDate>2024-04-16</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-16</startDate>
            <endDate>2024-04-16</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-33">0000200406</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-34">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K/A</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-04-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Johnson &amp; Johnson</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">NJ</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">1-3215</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">22-1024240</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">One Johnson &amp; Johnson Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">New Brunswick</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">08933</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">732</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">524-0400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-17">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="c-2" id="f-18">Common Stock, Par Value $1.00</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-19">JNJ</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-20">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-21">0.650% Notes Due May 2024</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-22">JNJ24C</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-23">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-4" id="f-24">5.50% Notes Due November 2024</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-4" id="f-25">JNJ24BP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-4" id="f-26">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-5" id="f-27">1.150% Notes Due November 2028</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-5" id="f-28">JNJ28</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-5" id="f-29">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-6" id="f-30">1.650% Notes Due May 2035</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-6" id="f-31">JNJ35</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-6" id="f-32">NYSE</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
